Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 12.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 25 mg/ml (as methotrexate sodium) - solution for injection - 7.5 mg/0.3ml - active: methotrexate 25 mg/ml (as methotrexate sodium) excipient: sodium chloride sodium hydroxide water for injection - methotrexate may be of value in the symptomatic control of server, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

Kanada - İngilizce - Health Canada

pfizer canada ulc - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Kanada - İngilizce - Health Canada

pfizer canada ulc - methotrexate (methotrexate sodium) - solution - 10mg - methotrexate (methotrexate sodium) 10mg - antineoplastic agents

Kanada - İngilizce - Health Canada

pfizer canada ulc - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Kanada - İngilizce - Health Canada

pfizer canada ulc - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Kanada - İngilizce - Health Canada

uman pharma inc - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - tablet - 10 milligram(s) - methotrexate